Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative, MET-Positive Gastroesophageal Cancer
Brief Summary: This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with 5-fluorouracil, folinic Acid, and oxaliplatin (mFOLFOX6) in participants with metastatic human epidermal growth receptor (HER) 2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Participants will be randomized in a 1:1 ratio to receive either onartuzumab or placebo in combination with mFOLFOX6. Participants may continue to receive onartuzumab or placebo until disease progression, unacceptable toxicity, participant or physician decision to discontinue treatment.


Options:
A: Arm Label: Arm A: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib plus capecitabine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Arm A: Lapatinib | Intervention Type: DRUG; Name: Lapatinib plus capecitabine; Assigned to Arm(s): Arm B
B: Arm Label: Surgery + HIPEC + Systemic Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin, Procedure: Gastrectomy and/or metastasectomy | Arm Label: Systemic Chemotherapy Alone; Type: EXPERIMENTAL; Interventions: Drug: Oxaliplatin, Drug: Irinotecan, Drug: 5-Fluorouracil, Drug: Leucovorin | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy, Systemic Chemotherapy Alone | Intervention Type: PROCEDURE; Name: Gastrectomy and/or metastasectomy; Assigned to Arm(s): Surgery + HIPEC + Systemic Chemotherapy
C: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Onartuzumab+mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluoruracil, Drug: Folinic acid, Drug: Onartuzumab, Drug: Oxaliplatin | Arm Label: Placebo+mFOLFOX6; Type: PLACEBO_COMPARATOR; Interventions: Drug: 5-Fluoruracil, Drug: Folinic acid, Drug: Oxaliplatin, Drug: Placebo | Intervention Type: DRUG; Name: 5-Fluoruracil; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Folinic acid; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Onartuzumab; Assigned to Arm(s): Onartuzumab+mFOLFOX6 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Onartuzumab+mFOLFOX6, Placebo+mFOLFOX6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+mFOLFOX6

Answer: D